Omalizumab treatment in asthma-COPD overlap syndrome
Omalizumab treatment in asthma-COPD overlap syndrome
复制标题
DOI：
10.1080/02770903.2016.1178281
复制
发表时间：
2016-12-01
影响因子：
1.9
通讯作者：
Cilli, Aykut
中科院分区：
文献类型：
--
作者：
Tat, Tugba Songul;Cilli, Aykut
简介：哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）是一种人们知之甚少的疾病，其发病率和死亡率不断增加。目前，ACOS最有效的治疗方法尚不清楚，奥马珠单抗治疗ACOS尚未见报道。方法：作为回顾性病例研究，我们报告了 3 例 ACOS 患者使用抗 IgE、奥马珠单抗治疗的经验。结果：奥马珠单抗治疗一年后，患者的哮喘发作率和住院率显着降低，哮喘控制测试结果也更好。结论：我们的研究表明，奥马珠单抗可能是治疗 ACOS 患者的一种有效且安全的疗法。然而，还需要更大规模的随机试验。
Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. Methods: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. Results: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. Conclusion: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.